Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care
Sponsor: Whitman-Walker Institute
Summary
The purpose of this study is to assess adherence to home-delivered long-acting injectable rilpivirine/cabotegravir (Cabenuva) among people living with HIV enrolled in the Mobile Outreach Retention and Engagement (MORE) program at Whitman-Walker Health due to significant barriers to being retained in care; the MORE program provides supportive services including dedicated care navigation, transportation assistance, and mobile/home-delivered care. The investigators will examine the equivalence of treatment outcomes among patients receiving injectable treatment within the MORE program as compared to those of patients receiving Cabenuva in standard care at Whitman-Walker Health.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
180
Start Date
2023-11-01
Completion Date
2025-06-30
Last Updated
2024-04-25
Healthy Volunteers
Not specified
Conditions
Interventions
rilpivirine/cabotegravir
WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
Locations (2)
Whitman-Walker 1525 Clinic
Washington D.C., District of Columbia, United States
Whitman-Walker Max Robinson Center
Washington D.C., District of Columbia, United States